| Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation F Wang, J Travins, B DeLaBarre, V Penard-Lacronique, S Schalm, ... Science 340 (6132), 622-626, 2013 | 615 | 2013 |
| Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA) C Preudhomme, C Sagot, N Boissel, JM Cayuela, I Tigaud, S de Botton, ... Blood 100 (8), 2717-2723, 2002 | 541 | 2002 |
| Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia EM Stein, CD DiNardo, DA Pollyea, AT Fathi, GJ Roboz, JK Altman, ... Blood 130 (6), 722-731, 2017 | 433 | 2017 |
| Incidence, clinical features, and outcome of alltrans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia S De Botton, H Dombret, M Sanz, J San Miguel, D Caillot, R Zittoun, ... Blood 92 (8), 2712-2718, 1998 | 361 | 1998 |
| Platelet formation is the consequence of caspase activation within megakaryocytes S de Botton, S Sabri, E Daugas, Y Zermati, JE Guidotti, O Hermine, ... Blood 100 (4), 1310-1317, 2002 | 350 | 2002 |
| Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine R Itzykson, S Thépot, B Quesnel, F Dreyfus, O Beyne-Rauzy, P Turlure, ... Blood 117 (2), 403-411, 2011 | 335 | 2011 |
| Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML) N Boissel, H Leroy, B Brethon, N Philippe, S De Botton, A Auvrignon, ... Leukemia 20 (6), 965, 2006 | 328 | 2006 |
| Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience L Ades, A Guerci, E Raffoux, M Sanz, P Chevallier, S Lapusan, C Recher, ... Blood 115 (9), 1690-1696, 2010 | 255 | 2010 |
| Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype N Boissel, A Renneville, V Biggio, N Philippe, X Thomas, JM Cayuela, ... Blood 106 (10), 3618-3620, 2005 | 247 | 2005 |
| Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML CD DiNardo, EM Stein, S de Botton, GJ Roboz, JK Altman, AS Mims, ... New England Journal of Medicine 378 (25), 2386-2398, 2018 | 222 | 2018 |
| Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes F Damm, O Kosmider, V Gelsi-Boyer, A Renneville, N Carbuccia, ... Blood 119 (14), 3211-3218, 2012 | 221 | 2012 |
| TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia O Kosmider, V Gelsi-Boyer, C Racoeur, V Jooste, N Vey, B Quesnel, ... Haematologica 94 (12), 1676-1681, 2009 | 208 | 2009 |
| Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results L Ades, MA Sanz, S Chevret, P Montesinos, P Chevallier, E Raffoux, ... Blood 111 (3), 1078-1084, 2008 | 204 | 2008 |
| Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial) D Caillot, A Thiébaut, R Herbrecht, S de Botton, A Pigneux, F Bernard, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2007 | 191 | 2007 |
| Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group L Adès, S Chevret, E Raffoux, S de Botton, A Guerci, A Pigneux, ... Journal of clinical oncology 24 (36), 5703-5710, 2006 | 187 | 2006 |
| Ecto‐calreticulin in immunogenic chemotherapy M Obeid, A Tesniere, T Panaretakis, R Tufi, N Joza, P Van Endert, ... Immunological reviews 220 (1), 22-34, 2007 | 181 | 2007 |
| Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter … C Gardin, P Turlure, T Fagot, X Thomas, C Terre, N Contentin, E Raffoux, ... Blood 109 (12), 5129-5135, 2007 | 178 | 2007 |
| High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group AL Taksin, O Legrand, E Raffoux, T De Revel, X Thomas, N Contentin, ... Leukemia 21 (1), 66, 2007 | 168 | 2007 |
| Acute leukemia during pregnancy: a report on 37 patients and a review of the literature Y Chelghoum, N Vey, E Raffoux, F Huguet, A Pigneux, B Witz, C Pautas, ... Cancer 104 (1), 110-117, 2005 | 153 | 2005 |
| Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial S de Botton, S Chevret, M Sanz, H Dombret, X Thomas, A Guerci, M Fey, ... British journal of haematology 111 (3), 801-806, 2000 | 151 | 2000 |
